Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer

Dow Jones

2024/12/13

By Paul Ziobro

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.

Berger had held the same role at Sanofi, where he was also global head of development, leading development science strategy and operations across the company's therapeutic area of focus. Prior to that, Berger held senior development roles at Atara, Genentech, Bayer and Amgen.

The Foster City, Calif.-based biopharmaceutical company said that Berger will be responsible for its virology, oncology and inflammation portfolio and will also oversee the company's global-development and medical-affairs organizations.

Gilead in July said that Parsey, who joined the company in 2019, would leave the company in early 2025.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

December 12, 2024 17:57 ET (22:57 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2491365374"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491365374\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491365374?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-13 06:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491365374","market":"fut","top_or_hot":-1,"title":"Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Paul Ziobro \n</p>\n<pre>\n \n</pre>\n<p>\n  Gilead Sciences named former <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. \n</p>\n<p>\n  Berger had held the same role at Sanofi, where he was also global head of development, leading development science strategy and operations across the company's therapeutic area of focus. Prior to that, Berger held senior development roles at Atara, Genentech, Bayer and Amgen. \n</p>\n<p>\n  The Foster City, Calif.-based biopharmaceutical company said that Berger will be responsible for its virology, oncology and inflammation portfolio and will also oversee the company's global-development and medical-affairs organizations. \n</p>\n<p>\n  Gilead in July said that Parsey, who joined the company in 2019, would leave the company in early 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2024 17:57 ET (22:57 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences Names Sanofi's Berger as Next Chief Medical Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-13 06:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Paul Ziobro \n</p>\n<pre>\n \n</pre>\n<p>\n  Gilead Sciences named former <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. \n</p>\n<p>\n  Berger had held the same role at Sanofi, where he was also global head of development, leading development science strategy and operations across the company's therapeutic area of focus. Prior to that, Berger held senior development roles at Atara, Genentech, Bayer and Amgen. \n</p>\n<p>\n  The Foster City, Calif.-based biopharmaceutical company said that Berger will be responsible for its virology, oncology and inflammation portfolio and will also oversee the company's global-development and medical-affairs organizations. \n</p>\n<p>\n  Gilead in July said that Parsey, who joined the company in 2019, would leave the company in early 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2024 17:57 ET (22:57 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491365374","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491365374","pubTimestamp":1734044220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.Berger had held the same role at Sanofi, where he was also global head of development, leading development science strategy and operations across the company's therapeutic area of focus. Prior to that, Berger held senior development roles at Atara, Genentech, Bayer and Amgen.The Foster City, Calif.-based biopharmaceutical company said that Berger will be responsible for its virology, oncology and inflammation portfolio and will also oversee the company's global-development and medical-affairs organizations.Gilead in July said that Parsey, who joined the company in 2019, would leave the company in early 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","GILD":"吉利德科学","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4007":"制药","BK4583":"猴痘概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4532":"文艺复兴科技持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4139":"生物科技","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4566":"资本集团","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4578":"CAR-T","LU0058720904.USD":"联博国际健康护理基金A","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SNYNF":"Sanofi","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD"},"translate_title":"吉利德科学任命赛诺菲的伯杰为下一任首席医疗官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1,"SNYNF":1},"content_text":"By Paul Ziobro \n\n\n \n\n\n  Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. \n\n\n  Berger had held the same role at Sanofi, where he was also global head of development, leading development science strategy and operations across the company's therapeutic area of focus. Prior to that, Berger held senior development roles at Atara, Genentech, Bayer and Amgen. \n\n\n  The Foster City, Calif.-based biopharmaceutical company said that Berger will be responsible for its virology, oncology and inflammation portfolio and will also oversee the company's global-development and medical-affairs organizations. \n\n\n  Gilead in July said that Parsey, who joined the company in 2019, would leave the company in early 2025. \n\n\n \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2024 17:57 ET (22:57 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}